A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity
- PMID: 21396910
- DOI: 10.1016/j.bbrc.2011.03.030
A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity
Abstract
We previously reported that novel targeted "hybrid peptide" in which epidermal growth factor receptor (EGFR) binding peptide was conjugated with lytic-type peptide had selective cytotoxic activity to EGFR expressing cancer cell lines, and in vivo analysis revealed that this EGFR-lytic peptide displayed significant antitumor activity in a xenograft model of human breast cancer which was resistant to tyrosine kinase inhibitor drugs. As an attempt to improve the selective anticancer activity of EGFR-lytic peptide, we modified the EGFR-binding peptide through introducing the mutation of amino acid according to biophysical analysis by biomolecular interaction and circular dichroism (CD) spectra. When cytotoxic activity of EGFR-lytic or EGFR(2R)-lytic hybrid peptides was investigated in various human cancer and normal cell lines, it was demonstrated that EGFR(2R)-lytic, in which second histidine (H) of EGFR-binding peptide was replaced to arginine (R) had 1.2-1.9-fold higher cytotoxic activity than that of original EGFR-lytic peptide. In vivo analysis also revealed that this modified peptide displayed significant antitumor activity at as low as 1 mg/kg dosage. These results suggest that mutated arginine on EGFR-lytic peptide produces higher binding ability to EGFR on cancer cells, and thereby the improved anticancer activity.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Characterization of antilytic peptide antibody: application for the detection of lytic-based hybrid peptide in serum samples.J Pept Sci. 2011 Jul;17(7):493-8. doi: 10.1002/psc.1349. Epub 2011 Feb 24. J Pept Sci. 2011. PMID: 21351323
-
A novel hybrid peptide targeting EGFR-expressing cancers.Eur J Cancer. 2011 Mar;47(5):773-83. doi: 10.1016/j.ejca.2010.10.021. Epub 2010 Nov 26. Eur J Cancer. 2011. PMID: 21112771
-
Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer.Biochem Biophys Res Commun. 2011 Oct 14;414(1):60-6. doi: 10.1016/j.bbrc.2011.09.021. Epub 2011 Sep 14. Biochem Biophys Res Commun. 2011. PMID: 21945444
-
Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics.Mol Cancer Ther. 2003 Nov;2(11):1243-55. Mol Cancer Ther. 2003. PMID: 14617798 Review.
-
Peptide-Based Therapeutics for Oncology.Pharmaceut Med. 2019 Feb;33(1):9-20. doi: 10.1007/s40290-018-0261-7. Pharmaceut Med. 2019. PMID: 31933267 Review.
Cited by
-
Evolutionary analysis of p38 stress-activated kinases in unicellular relatives of animals suggests an ancestral function in osmotic stress.Open Biol. 2023 Jan;13(1):220314. doi: 10.1098/rsob.220314. Epub 2023 Jan 18. Open Biol. 2023. PMID: 36651171 Free PMC article.
-
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Curr Cancer Drug Targets. 2012 Mar;12(3):197-209. doi: 10.2174/156800912799277557. Curr Cancer Drug Targets. 2012. PMID: 22268382 Free PMC article. Review.
-
The dual interaction of antimicrobial peptides on bacteria and cancer cells; mechanism of action and therapeutic strategies of nanostructures.Microb Cell Fact. 2022 Jun 18;21(1):118. doi: 10.1186/s12934-022-01848-8. Microb Cell Fact. 2022. PMID: 35717207 Free PMC article. Review.
-
Design of Highly Fluorinated Peptides for Cell-based 19F NMR.Bioconjug Chem. 2023 Aug 16;34(8):1477-1485. doi: 10.1021/acs.bioconjchem.3c00245. Epub 2023 Jul 31. Bioconjug Chem. 2023. PMID: 37523271 Free PMC article.
-
Rational Design of Hybrid Peptides: A Novel Drug Design Approach.Curr Med Sci. 2019 Jun;39(3):349-355. doi: 10.1007/s11596-019-2042-2. Epub 2019 Jun 17. Curr Med Sci. 2019. PMID: 31209802 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous